Findings

What do systematic reviews say?

30 questions · 30 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 26.7%GRADE not reported 6 · 20%Very low 3 · 10%Low 10 · 33.3%Moderate 2 · 6.7%High 1 · 3.3%

Rilonacept vs indomethacin

Participant global assessment of success Not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs indomethacin

Withdrawals due to adverse events · acute gout

Rilonacept showed no clear difference in adverse events ‐ study withdrawals due to adverse events compared with indomethacin (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 0.51 [0.05, 5.47]
1 study · 151 participants
Low

Rilonacept vs indomethacin

Adverse events as N of participants with at least one adverse event objective · acute gout

Rilonacept showed no clear difference in adverse events ‐ participants with at least 1 adverse event compared with indomethacin (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.19 [0.75, 1.88]
1 study · 151 participants
Low

Rilonacept vs indomethacin

Pain ‐ change from baseline to 24 to 72 hours Assessed on numerical rating scale (0 = no pain; 10 = extreme pain) · acute gout

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 148 participants
Low

Rilonacept vs indomethacin

Inflammation ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Intracranial pressure (mmHg) · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury

1 finding from 1 review

Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Mortality one month after the start of therapy · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury

1 finding from 1 review

Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Adverse effects considered as serious by either the patient or the clinician · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury

1 finding from 1 review

Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Disability (measured by the Glasgow Outcome Scale; higher score is better) · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury

1 finding from 1 review

Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Intervention not reported

Differences in quality of life ( · adults presenting with elevated intracranial pressure secondary to a traumatic brain injury

1 finding from 1 review

Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported